{"transactions":[{"id":833690,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-03-19T18:25:33.000Z","date":"2026-03-17","kind":"sale","planned":false,"acquired":false,"shares":31492,"price":6.423,"value":202273.116,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 135,833 RSUs."}],"balance_after":300760,"source":{"system":"sec-edgar","filing":"0001610717-26-000123","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071726000123/form4.xml","form_type":"4"}},{"id":919637,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T16:25:27.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":250000,"derivative":{"exercise_price":6.09,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001610717-26-000041","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071726000041/form4.xml","form_type":"4"}},{"id":919636,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-04T16:25:27.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 218,958 RSUs."}],"balance_after":332252,"source":{"system":"sec-edgar","filing":"0001610717-26-000041","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071726000041/form4.xml","form_type":"4"}},{"id":1030650,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Performance Stock Units (PSUs)","published_at":"2025-09-30T18:37:42.000Z","date":"2025-09-26","kind":"grant","planned":false,"acquired":true,"shares":18150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":18150,"derivative":{"underlying":"Common Stock","underlying_shares":18150},"source":{"system":"sec-edgar","filing":"0001610717-25-000354","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000354/form4.xml","form_type":"4"}},{"id":1030649,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-30T18:37:42.000Z","date":"2025-09-26","kind":"grant","planned":false,"acquired":true,"shares":36300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from September 26, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":36300,"derivative":{"exercise_price":2.9,"expiration_date":"2035-09-25","underlying":"Common Stock","underlying_shares":36300},"source":{"system":"sec-edgar","filing":"0001610717-25-000354","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000354/form4.xml","form_type":"4"}},{"id":1108299,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Performance Stock Units","published_at":"2025-06-17T16:10:00.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":false,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each PSU represented a contingent right to receive one (1) share of common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each PSU represented a contingent right to receive one (1) share of common stock upon vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each PSU represented a contingent right to receive one (1) share of common stock upon vesting."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001610717-25-000235","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000235/form4.xml","form_type":"4"}},{"id":1108298,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-06-17T16:10:00.000Z","date":"2025-06-16","kind":"sale","planned":false,"acquired":false,"shares":13884,"price":2.689,"value":37334.076,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 158,958 restricted stock units."}],"balance_after":272252,"source":{"system":"sec-edgar","filing":"0001610717-25-000235","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000235/form4.xml","form_type":"4"}},{"id":1108297,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-06-17T16:10:00.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents the vesting of performance stock units (\"PSUs\") initially granted on February 2, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 158,958 restricted stock units."}],"balance_after":286136,"source":{"system":"sec-edgar","filing":"0001610717-25-000235","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000235/form4.xml","form_type":"4"}},{"id":1195881,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-20T16:31:34.000Z","date":"2025-03-18","kind":"sale","planned":false,"acquired":false,"shares":19512,"price":0.599,"value":11687.688,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 158,958 RSUs."}],"balance_after":248636,"source":{"system":"sec-edgar","filing":"0001610717-25-000082","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000082/form4.xml","form_type":"4"}},{"id":1276806,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-10T17:58:43.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/24th of the shares subject to the option vest on each monthly anniversary measured from the Vesting Commencement Date, such that 100% of the shares subject to the option will be fully vested and exercisable on the second anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":115000,"derivative":{"exercise_price":0.864,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001610717-25-000020","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000020/form4.xml","form_type":"4/A","original_submission_date":"2025-02-06"}},{"id":1276805,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-10T17:58:43.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Form 4 filed by the Reporting Person on February 6, 2025 incorrectly reflected the number of securities acquired in Box 4 of Table I and Box 5 of Table II and consequently the amount beneficially owned reflected in Box 5 of Table I and Box 9 of Table II.  The number of securities acquired and the amount beneficially owned following reported transactions has been adjusted in this Form 4/A to correct the aforementioned errors. Except as otherwise noted in this footnote, all other information disclosed in the Reporting Person's original Form 4 was accurately reported."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from February 4, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Form 4 filed by the Reporting Person on February 6, 2025 incorrectly reflected the number of securities acquired in Box 4 of Table I and Box 5 of Table II and consequently the amount beneficially owned reflected in Box 5 of Table I and Box 9 of Table II.  The number of securities acquired and the amount beneficially owned following reported transactions has been adjusted in this Form 4/A to correct the aforementioned errors. Except as otherwise noted in this footnote, all other information disclosed in the Reporting Person's original Form 4 was accurately reported."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Form 4 filed by the Reporting Person on February 6, 2025 incorrectly reflected the number of securities acquired in Box 4 of Table I and Box 5 of Table II and consequently the amount beneficially owned reflected in Box 5 of Table I and Box 9 of Table II.  The number of securities acquired and the amount beneficially owned following reported transactions has been adjusted in this Form 4/A to correct the aforementioned errors. Except as otherwise noted in this footnote, all other information disclosed in the Reporting Person's original Form 4 was accurately reported."}],"balance_after":150000,"derivative":{"exercise_price":0.864,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001610717-25-000020","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000020/form4.xml","form_type":"4/A","original_submission_date":"2025-02-06"}},{"id":1276804,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-10T17:58:43.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":57500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Constitute RSUs for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 50% of the RSUs vest annually on March 15 of each year, with the first 50% vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Form 4 filed by the Reporting Person on February 6, 2025 incorrectly reflected the number of securities acquired in Box 4 of Table I and Box 5 of Table II and consequently the amount beneficially owned reflected in Box 5 of Table I and Box 9 of Table II.  The number of securities acquired and the amount beneficially owned following reported transactions has been adjusted in this Form 4/A to correct the aforementioned errors. Except as otherwise noted in this footnote, all other information disclosed in the Reporting Person's original Form 4 was accurately reported."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 201,666 RSUs."}],"balance_after":268148,"source":{"system":"sec-edgar","filing":"0001610717-25-000020","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000020/form4.xml","form_type":"4/A","original_submission_date":"2025-02-06"}},{"id":1276803,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-10T17:58:43.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Form 4 filed by the Reporting Person on February 6, 2025 incorrectly reflected the number of securities acquired in Box 4 of Table I and Box 5 of Table II and consequently the amount beneficially owned reflected in Box 5 of Table I and Box 9 of Table II.  The number of securities acquired and the amount beneficially owned following reported transactions has been adjusted in this Form 4/A to correct the aforementioned errors. Except as otherwise noted in this footnote, all other information disclosed in the Reporting Person's original Form 4 was accurately reported."},{"field":"shares","element":"transactionShares","label":"F2","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Form 4 filed by the Reporting Person on February 6, 2025 incorrectly reflected the number of securities acquired in Box 4 of Table I and Box 5 of Table II and consequently the amount beneficially owned reflected in Box 5 of Table I and Box 9 of Table II.  The number of securities acquired and the amount beneficially owned following reported transactions has been adjusted in this Form 4/A to correct the aforementioned errors. Except as otherwise noted in this footnote, all other information disclosed in the Reporting Person's original Form 4 was accurately reported."}],"balance_after":210648,"source":{"system":"sec-edgar","filing":"0001610717-25-000020","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000020/form4.xml","form_type":"4/A","original_submission_date":"2025-02-06"}},{"id":1280463,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-06T17:57:43.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/24th of the shares subject to the option vest on each monthly anniversary measured from the Vesting Commencement Date, such that 100% of the shares subject to the option will be fully vested and exercisable on the second anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":115000,"derivative":{"exercise_price":0.864,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001610717-25-000019","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000019/form4.xml","form_type":"4"}},{"id":1280462,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-06T17:57:43.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from February 4, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":140000,"derivative":{"exercise_price":0.864,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001610717-25-000019","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000019/form4.xml","form_type":"4"}},{"id":1280461,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-06T17:57:43.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":57500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Constitute RSUs for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 50% of the RSUs vest annually on March 15 of each year, with the first 50% vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 196,666 RSUs."}],"balance_after":263148,"source":{"system":"sec-edgar","filing":"0001610717-25-000019","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000019/form4.xml","form_type":"4"}},{"id":1280460,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-06T17:57:43.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":205648,"source":{"system":"sec-edgar","filing":"0001610717-25-000019","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000019/form4.xml","form_type":"4"}},{"id":1425671,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Performance Stock Units (PSUs)","published_at":"2024-08-22T18:01:09.000Z","date":"2024-08-20","kind":"exercise","planned":false,"acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001610717-24-000435","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071724000435/form4.xml","form_type":"4"}},{"id":1425670,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-08-22T18:01:09.000Z","date":"2024-08-20","kind":"sale","planned":false,"acquired":false,"shares":4181,"price":1.2291,"value":5138.8671,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs reported herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 109,166 restricted stock units."}],"balance_after":175648,"source":{"system":"sec-edgar","filing":"0001610717-24-000435","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071724000435/form4.xml","form_type":"4"}},{"id":1425669,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-08-22T18:01:09.000Z","date":"2024-08-20","kind":"exercise","planned":false,"acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 109,166 restricted stock units."}],"balance_after":179829,"source":{"system":"sec-edgar","filing":"0001610717-24-000435","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071724000435/form4.xml","form_type":"4"}},{"id":1564987,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-03-21T16:37:36.000Z","date":"2024-03-19","kind":"sale","planned":false,"acquired":false,"shares":12795,"price":2.0855,"value":26683.9725,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 109,166 restricted stock units."}],"balance_after":168579,"source":{"system":"sec-edgar","filing":"0001610717-24-000176","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071724000176/form4.xml","form_type":"4"}},{"id":1675437,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Performance Stock Units (PSUs)","published_at":"2024-01-19T20:38:49.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Performance-Based Restricted Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Performance-Based Restricted Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each Performance-Based Restricted Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/2 of the PSUs vest upon the achievement of each of two clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":75000,"derivative":{"underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001610717-24-000032","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071724000032/form4.xml","form_type":"4"}},{"id":1675436,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-19T20:38:49.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":122500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from January 18, 2024 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":122500,"derivative":{"exercise_price":1.68,"expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":122500},"source":{"system":"sec-edgar","filing":"0001610717-24-000032","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071724000032/form4.xml","form_type":"4"}},{"id":1675435,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-19T20:38:49.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":26250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2025, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 143,125 RSUs."}],"balance_after":181374,"source":{"system":"sec-edgar","filing":"0001610717-24-000032","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071724000032/form4.xml","form_type":"4"}},{"id":1701172,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-12-22T16:14:32.000Z","date":"2023-12-20","kind":"sale","planned":false,"acquired":false,"shares":4077,"price":1.3805,"value":5628.2985,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs previously reported on December 19, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 116,875 restricted stock units."}],"balance_after":155124,"source":{"system":"sec-edgar","filing":"0001610717-23-000422","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071723000422/form4.xml","form_type":"4"}},{"id":1705306,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Performance Stock Units (PSUs)","published_at":"2023-12-19T19:54:36.000Z","date":"2023-12-17","kind":"exercise","planned":false,"acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents partial vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents partial vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. In connection with the vesting reported herein, 50% of the PSUs vested upon achievement of a certain performance-based milestone. The remaining 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. In connection with the vesting reported herein, 50% of the PSUs vested upon achievement of a certain performance-based milestone. The remaining 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024."}],"balance_after":11250,"derivative":{"underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001610717-23-000408","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071723000408/form4.xml","form_type":"4"}},{"id":1705305,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-12-19T19:54:36.000Z","date":"2023-12-17","kind":"exercise","planned":false,"acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents partial vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 116,875 restricted stock units."}],"balance_after":159201,"source":{"system":"sec-edgar","filing":"0001610717-23-000408","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071723000408/form4.xml","form_type":"4"}},{"id":1774867,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-09-22T19:16:52.000Z","date":"2023-09-22","kind":"sale","planned":false,"acquired":false,"shares":4119,"price":1.3003,"value":5355.9357,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 116,875 restricted stock units."}],"balance_after":147951,"source":{"system":"sec-edgar","filing":"0001610717-23-000299","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071723000299/form4.xml","form_type":"4"}},{"id":1774866,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-09-22T19:16:52.000Z","date":"2023-09-20","kind":"grant","planned":false,"acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents Performance Stock Units (\"PSUs\") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The second milestone vesting condition was determined to be satisfied upon which the remaining 50% of the PSUs vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 116,875 restricted stock units."}],"balance_after":152070,"source":{"system":"sec-edgar","filing":"0001610717-23-000299","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071723000299/form4.xml","form_type":"4"}},{"id":1935942,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-03-29T19:54:34.000Z","date":"2023-03-22","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/4th of the RSUs vest annually on March 15 of each year, with the first 1/4th vesting on March 15, 2024, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 116,875 RSUs."}],"balance_after":140820,"source":{"system":"sec-edgar","filing":"0001140361-23-014592","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000114036123014592/form4.xml","form_type":"4"}}]}